111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
111, Inc. (NASDAQ: YI) reported its unaudited financial results for Q4 and FY 2022, showcasing a strong growth trajectory. In Q4, net revenues reached RMB4.1 billion (US$601.4 million), up 19.9% YoY, while gross segment profit increased by 23.8%. The company's operational loss narrowed to RMB108.4 million (US$15.7 million), a slight increase from last year, but as a percentage of revenues, it improved to 2.61%. For FY 2022, revenues totaled RMB13.5 billion (US$2.0 billion), an 8.8% increase, with gross margin improving from 5.0% to 6.2%. The company achieved positive operating cash flow for the second consecutive quarter, indicating stronger operational efficiency.